Prestige Consumer Healthcare reports record FY2022 revenue $1.087B, adj. EPS $4.06, authorizes $50M buyback

Prestige Consumer Healthcare Inc.

2022-FY EPS reported $4.04 revenue$1,086,812,000

Q4 revenue $266.9M (+12.3% YoY); full-year revenue $1,086.8M (+15.2% YoY).
Full-year GAAP diluted EPS $4.04; adjusted diluted EPS $4.06, up 25.3%.
Record non-GAAP free cash flow $253.7M; operating cash flow $259.9M.
Initial FY2023 outlook: revenue ~$1.125B, diluted EPS $4.18-$4.23, FCF $260M+.
Board authorized $50M share repurchase program through May 2023; net leverage 3.8x.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.